Gilead Sciences

NASDAQ: GILD
$66.94
-$0.04 (-0.1%)
Closing price January 22, 2021
Tuesday's top analyst upgrades and downgrades included Airbnb, American Express, Arch Capital, Carlyle, Darden Restaurants, Facebook, Eli Lilly and Nio.
As earnings season begins, Lululemon Athletica and other companies are updating guidance for the quarter just ended and for the 2020 fiscal year.
Although the markets may be falling, 24/7 Wall St. is taking a look at some big analyst calls that we have seen so far on Monday.
Thursday's top analyst upgrades and downgrades included AT&T, Boeing, ConocoPhillips, Gilead Sciences, Illumina, Lam Research, Raytheon Technologies and Yum Brands.
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Thursday's top analyst upgrades and downgrades included Amgen, Boeing, eBay, Etsy, Fastly, Fiverr, Ford, General Electric, Gilead Sciences, Pinterest and Six Flags.
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
Some battered stocks that have not risen back to their highs are attracting some interesting analyst upgrades and new coverage.
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
24/7 Wall St. has been reviewing many sectors for leadership heading into earnings. One area that can offer some defensive strategies is biotech and pharmaceuticals.